Antiviral Drug News and Research RSS Feed - Antiviral Drug News and Research

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157. [More]
Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

Monash University and 60P Australia Pty Ltd, a subsidiary of 60° Pharmaceuticals LLC, have announced today an exclusive partnering deal, with 60P obtaining rights to develop the drug Fenretinide for dengue fever. [More]
UTMB researchers receive awards at American Society of Tropical Medicine and Hygiene meeting

UTMB researchers receive awards at American Society of Tropical Medicine and Hygiene meeting

Scientists at the University of Texas Medical Branch were recognized with prestigious awards for their contributions in research at the annual American Society of Tropical Medicine and Hygiene meeting. [More]
Experimental Ebola treatments to be trialled in West Africa next month

Experimental Ebola treatments to be trialled in West Africa next month

Médecins Sans Frontières/Doctors without Borders (MSF) have announced that three trials of Ebola therapies will begin in West Africa this December. [More]
UF Health researcher finds way to grow human norovirus

UF Health researcher finds way to grow human norovirus

Noroviruses are pernicious intestinal viruses. They cause violent vomiting and diarrhea, and people ill with the virus remain contagious up to three days after they seem to recover. [More]
Ebola screening and education stepped up amid fears of spiralling epidemic

Ebola screening and education stepped up amid fears of spiralling epidemic

The recent occurrences of Ebola cases outside Africa has led to fears of a global epidemic. The US Centers for Disease Control and Prevention (CDC) has estimated that the number of infections could rise to up to 1.4 million people by early next year without a massive global intervention to contain the virus. [More]
Semi-soft vaginal suppository provides drug-delivery vehicle to prevent spread of HIV

Semi-soft vaginal suppository provides drug-delivery vehicle to prevent spread of HIV

A unique method for delivering compounds that could positively impact the global battle against HIV and AIDS may be possible, thanks to researchers in Penn State's College of Agricultural Sciences. [More]
Hepatitis C could become a rare disease by 2036

Hepatitis C could become a rare disease by 2036

Effective new drugs and screening would make hepatitis C a rare disease by 2036, according to a computer simulation conducted by The University of Texas MD Anderson Cancer Center and the University of Pittsburgh Graduate School of Public Health. The results of the simulation are reported in the August 5 edition of the journal Annals of Internal Medicine. [More]
New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according to the results of two studies published in The Lancet. [More]
Viewpoints: Working for benefits; fears for a pill to prevent HIV; possible Medicaid strategy for Virginia

Viewpoints: Working for benefits; fears for a pill to prevent HIV; possible Medicaid strategy for Virginia

[Economist Robert] Moffitt noted in an email that "the work incentives in the government safety net have greatly increased over the last 20 years: less welfare payments if you don't work, and much greater government payments if you do." [More]
Research: Novel antiviral drug may reduce spread, severity of measles without vaccination

Research: Novel antiviral drug may reduce spread, severity of measles without vaccination

A novel antiviral drug may reduce the spread and severity of measles without a vaccination. Dr. Richard Plemper from the Institute for Biomedical Sciences at Georgia State University and Dr. Michael Natchus of the Emory Institute for Drug Discovery (EIDD) will be available to answer questions from the media at a live virtual press conference at 1 PM EDT, Wednesday, April 16th. [More]
Scientists develop novel antiviral drug that may prevent spreading of measles

Scientists develop novel antiviral drug that may prevent spreading of measles

A novel antiviral drug may protect people infected with the measles from getting sick and prevent them from spreading the virus to others, an international team of researchers says. [More]
Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza. [More]
Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

​The German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed the antiviral drug combination rilpivirine/emtricitabine/tenofovir. In early 2012, the combination was approved for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) who have not received previous antiretroviral treatment. [More]
New national research consortium focuses on better drug therapies for viral infections

New national research consortium focuses on better drug therapies for viral infections

Viral infections with limited or no treatment options can pose a major global health threat, but a new national research consortium centered at the University of Alabama at Birmingham is focused on the discovery of new and better drug therapies as these viruses emerge. [More]
Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus. [More]
TSRI scientists describe severe immune overreaction caused by flu infections

TSRI scientists describe severe immune overreaction caused by flu infections

Scientists at The Scripps Research Institute have mapped key elements of a severe immune overreaction—a “cytokine storm”—that can both sicken and kill patients who are infected with certain strains of flu virus. [More]
Commonly-used HIV drug kills HPV that leads to cervical cancer

Commonly-used HIV drug kills HPV that leads to cervical cancer

A commonly-used HIV drug has been shown to kill-off the human papilloma virus (HPV) that leads to cervical cancer in a world-first clinical trial led by The University of Manchester with Kenyatta National Hospital in Nairobi. [More]
Scientists identify factors that predict flu severity in patients

Scientists identify factors that predict flu severity in patients

St. Jude Children's Research Hospital scientists have identified a signature immune response that might help doctors identify which newly diagnosed influenza patients are most likely to develop severe symptoms and suffer poor outcomes. The findings also help explain why infants and toddlers are at elevated risk for flu complications. The research appears in the upcoming issue of the American Journal of Respiratory and Critical Care Medicine. [More]
CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today the Company has received approval from the United States Food and Drug Administration (FDA) to commence patient screening of a Phase 2b study of PRO 140, a monoclonal CCR5 antibody, for the treatment of patients with Human Immunodeficiency Virus Type 1. [More]